Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > IT IS ALREADY OVER> time to change our name again

<< Previous

Bullboard Posts

Next >>

Comment by bobbybittmanon Mar 08, 2022 1:23pm

94 Views

Post# 34496138

RE:IT IS ALREADY OVER> time to change our name again

yes chances are we will be strung along all year with promises i dont expect much at all but we might get lucky with this pump and dump and they could push it to 30 cents before dropping it down back to this level as it seems to be how most stocks on here play out because the market seems to be controlled by the few whales

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario